NATIONAL INSTITUTES OF HEALTH
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
Phase 2
Completed
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and UreterTransitional Cell Carcinoma of the BladderRegional Transitional Cell Cancer of the Renal Pelvis and UreterStage III Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerStage IV Bladder Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT00112671
- Locations
- π¨π¦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Phase 2
Completed
- Conditions
- Adult Extraskeletal OsteosarcomaAdult Malignant MesenchymomaAdult Extraskeletal ChondrosarcomaAdult FibrosarcomaAdult Alveolar Soft-part SarcomaAdult AngiosarcomaAdult LeiomyosarcomaAdult LiposarcomaRecurrent Adult Soft Tissue SarcomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00112463
Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome
- First Posted Date
- 2005-05-27
- Last Posted Date
- 2017-10-06
- Target Recruit Count
- 56
- Registration Number
- NCT00111956
- Locations
- πΊπΈ
Mass General Hospital, Boston, Massachusetts, United States
Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)
Completed
- Conditions
- Neurofibromatosis Type 1Legius Syndrome
- First Posted Date
- 2005-05-20
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 313
- Registration Number
- NCT00111384
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Central Nervous System Disease in HIV-infected Children on HAART
Completed
- Conditions
- Central Nervous System DiseasesHIV Infections
- First Posted Date
- 2005-05-06
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00110331
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase 3
Completed
- Conditions
- Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
- Interventions
- Other: placeboBiological: bevacizumabOther: laboratory biomarker analysis
- First Posted Date
- 2005-05-05
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1050
- Registration Number
- NCT00110214
- Locations
- πΊπΈ
Yale University, New Haven, Connecticut, United States
πΊπΈCancer and Leukemia Group B, Chicago, Illinois, United States
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Recurrent Mantle Cell Lymphoma
- Interventions
- Biological: rituximab
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 71
- Registration Number
- NCT00109967
- Locations
- πΊπΈ
Mobile Infirmary Medical Center, Mobile, Alabama, United States
πΊπΈSaint Mary Corwin Medical Center, Pueblo, Colorado, United States
πΊπΈGraham Hospital Association, Canton, Illinois, United States
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Phase 3
Completed
- Conditions
- Recurrent MelanomaStage IIIC Skin MelanomaMucosal MelanomaStage IIIA Skin MelanomaStage IIIB Skin MelanomaStage IV Skin Melanoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological StudyOther: Placebo
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 823
- Registration Number
- NCT00110019
- Locations
- πΊπΈ
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
πΊπΈBay Area Tumor Institute, Oakland, California, United States
πΊπΈKaiser Permanente-Redwood City, Redwood City, California, United States
Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Recurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00109824
- Locations
- πΊπΈ
Ohio State University Medical Center, Columbus, Ohio, United States
Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
Phase 2
Completed
- Conditions
- Recurrent Prostate CancerAdenocarcinoma of the Prostate
- Interventions
- Biological: incomplete Freund's adjuvantOther: laboratory biomarker analysis
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00109811
- Locations
- πΊπΈ
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States